|
Literatur zu RituximabRheumatoide ArthritisDie ersten Studien:De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G. Leandro MJ, Edwards JC, Cambridge G., Centre for Rheumatology, University College London, UK: Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.Ann Rheum Dis. 2002 Oct;61(10):883-8 Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004 Jun 17;350(25):2572-81. Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, Webster AD, Centre for Rheumatology, University College London, Arthur Stanley House, 40-50 Tottenham Street, London W1T 4NJ, UK: Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 2003 Aug;48(8):2146-54 Kneitz C, Wilhelm M, Tony HP, Medizinische Poliklinik der Universitat Wurzburg, Germany. DANCER-Studie:Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54:1390-1400 Emery P, A. Filipowicz-Sosnowska, L. Szczepanski, A. Racewicz, J. Schechtman, R. M., Fleischmann, R. Van Vollenhoven, N. F. Li, S. Agarwal, E. Hessey, T. M. Shaw: PRIMARY ANALYSIS OF A DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL OF RITUXIMAB, AN ANTI-CD20 MONOCLONAL ANTIBODY, IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING METHOTREXATE (DANCER TRIAL). EULAR 2005, Wien, OP0008 Emery P et al, EULAR 2006; OP0017 REFLEX-Studie:Cohen SB, M. Greenwald, M. R. Dougados, P. Emery, R. Furie, T. M. Shaw, M. C. Totoritis: Efficacy and Safety of Rituximab in Active R A Patients who Experienced an Inadequate Response to one or More Anti-TNFa Therapies (REFLEX Study). ACR/ARHP Annual Scientific Meeting; November 13-16, 2005; San Diego, CA. Abstract 1830. E. Keystone1, P. Emery2, C. G. Peterfy3, P. P. Tak4, S. Cohen5, M. Genovese6, S. Williams7, M. Totoritis8, M. Cravets8, T. Shaw7 J. M. Kremer1, H. Tony2, P. P. Tak3, M. Luggen4, X. Mariette5, E. Hessey6, D. McCabe7, S. Safa-Leathers6. S. B. Cohen1, M. Greenwald2, M. Dougados3, P. Emery4, R. Furie5, T. Shaw6, M. Totoritis7 S. Cohen1, P. Emery2, M. Greenwald3, M. Dougados4, R. Furie5, G. Burmester6, S. Williams7, M. Cravets8, F. Magrini7 G. R. Burmester1, E. M. Ruderman2, P. Durez3, J. Loveless4, T. K. Kvien5, C. Jackson6, L. Burke7, M. Cravets8, A. M. White7 Verträglichkeit und Therapiesicherheit:Higashida J et al: Safety and Efficacy of Rituximab in Patients with Rheumatoid Arthritis Refractory to Disease Modifying Antirheumatic Drugs and Anti-Tumor Necrosis Factor-alpha-Treatment. J Rheumatol 2005;32:2109-15 Kimby E: Tolerability and safety of rituximab (MabThera®). Cancer Treatment Reviews Kavanaugh AF, Center for Innovative Therapy, University of California San Diego, San Diego, California 92093-0943, USA. Hainsworth JD., Sarah Cannon Cancer Center, Nashville, Tennessee, USA. Wirkmechanismus:Szodoray P, Alex P, Dandapani V, Nakken B, Pesina J, Kim X, Wallis GL, Wilson PC, Jonsson R, Centola M., Broegelmann Research Laboratory, The Gade Institute, University of Bergen, Armauer Hansen Building, N-5021 Bergen, Norway, Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC., University College London, London, UK. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. , University College London, Center for Rheumatology, London, UK. Panayi GS, Hainsworth JD, Looney RJ, Keystone EC., Department of Rheumatology, Guy's, King's and St Thomas' Medical School, Guy's Hospital, St Thomas' Street, London SE1 9RT, UK. Dörner T., Charite University Hospital Berlin and the Deutsches Rheumaforschungszentrum, Berlin, Germany. Pescovitz MD., Department of Surgery, Indiana University, Indianapolis, IN, USA.
Systemischer Lupus erythematodes (SLE)Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I., University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA. Sfikakis PP, Boletis JN, Tsokos GC., First Department of Propedeutic and Internal Medicine, Athens University Medical School, Greece, Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. , Centre for Rheumatology, University College London, London, UK: B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.Rheumatology (Oxford). 2005 Dec;44(12):1542-5. Epub 2005 Sep 27 Ng KP, Leandro MJ, Edwards JC, Ehrenstein MR, Cambridge G, Isenberg DA. , Centre for Rheumatology, University College London, Arthur Stanley House, 40-50 Tottenham Street, London W1T 4NJ, UK: Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis. 2006 Jul;65(7):942-5. Epub 2005 Nov 3: Rituximab provides new hope for people with lupus. Medical Study News. Published: Thursday, 9-Jun-2005, Kindlicher LupusWillems M, Haddad E, Niaudet P, Kone-Paut I, Bensman A, Cochat P, Deschenes G, Fakhouri F, Leblanc T, Llanas B, Loirat C, Pillet P, Ranchin B, Salomon R, Ulinski T, Bader-Meunier B; French Pediatric-Onset SLE Study Group, Department of Pediatrics, Hopital de Bicetre, Le Kremlin Bicetre, France. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr. 2006 May;148(5):623-627 Marks SD, Patey S, Brogan PA, Hasson N, Pilkington C, Woo P, Tullus K. Weitere ErkrankungenWeinreb N, Rabinowitz A, Dellaripa PF. Beneficial response to rituximab in refractory Felty Syndrome.J Clin Rheumatol. 2006 Feb;12(1):48 Bhatia A, Ell PJ, Edwards JC: Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis. 2005 Jul;64(7):1099-100. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, Vissink A, Kallenberg CG, Bootsma H, Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, Groningen, The Netherlands. Omdal R, Wildhagen K, Hansen T, Gunnarsson R, Kristoffersen G, Department of Internal Medicine, Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway. Eriksson P., Department of Rheumatology, University Hospital, Linkoping, Sweden. Keogh KA, Wylam ME, Stone JH, Specks U, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA: Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.Arthritis Rheum. 2005 Jan;52(1):262-8 Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U, Division of Pulmonary and Critical Care Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA: Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med. 2006 Jan 15;173(2):180-7. Epub 2005 Oct 13 Ahmadi-Simab K, Lamprecht P, Nolle B, Ai M, Gross WL: Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis. 2005 Jul;64(7):1087-8 Übersichten zu Rituximab und zur B-Zell-DepletionEdwards JC, Leandro MJ, Cambridge G., Centre for Rheumatology, Arthur Stanley House, University College London, 40-50 Tottenham Street, London W1T 4NJ, UK., Edwards JC, Leandro MJ, Cambridge G., Centre for Rheumatology, University College London, Arthur Stanley House, 40-50 Tottenham Street, London W1T 4NJ, UK., Clark EA, Ledbetter JA, Department of Immunology and National Primate Research Center, Box 357330, University of Washington, Seattle, WA 98195, USA, Looney RJ, Anolik J, Sanz I. , Department of Medicine, University of Rochester, Box 695, 601 Elmwood Avenue, Rochester, NY 14642, USA, Looney RJ., University of Rochester, 601 Elmwood Avenue, Rm G-6454, Rochester, NY 14642, USA, Gorman C, Leandro M, Isenberg D., Centre for Rheumatology, The Middlesex Hospital, University College London, UK: B cell depletion in autoimmune disease. Arthritis Res Ther. 2003;5 Suppl 4:S17-21. Epub 2003 Oct 2 Kneitz C, Wilhelm M, Tony HP., Medizinische Poliklinik der Universitat Wurzburg, Germany, Chambers SA, Isenberg D., Centre for Rheumatology, The Middlesex Hospital, University College, London, UK: Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus. 2005;14(3):210-4 Rastetter W, Molina A, White CA., IDEC Pharmaceuticals Corporation, 3030 Callan Road, San Diego, California 92121, USA: Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med. 2004;55:477-503 Goronzy JJ, Weyand CM., Departments of Medicine and Immunology, Mayo Clinic, Rochester, MN, USA, Keystone EC, The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, The Joseph and Wolf Lebovic Building, 2nd Floor, Room 2-006, 60 Murray Street, Toronto, Ontario M5G 1X5, Canada. Looney RJ., Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA. Brezinschek HP, Brickmann K, Yazdani-Biuki B, Dorner T, Graninger WB, Brezinschek RI. Autor: Priv. Doz. Dr. med. H.E. Langer |
|||||
|
||||||
gf.ferraccioli(at)med.uniud.it
hier online abrufbar
Druckversion
